Clinical Development for CNS and Neurological Diseases

Driving successful outcomes for CNS and Neurology trials is challenging

Second, only to Oncology, CNS, and Neurology clinical trials are incredibly complex and complicated to navigate. CNS trials are plagued with high failure rates at or before phase III, and therefore require careful risk mitigation throughout trial design and execution with close regulatory agency collaboration.

That is why Veristat has built a team of scientific-minded experts who have supported more than 250 CNS/Neurology projects, including drug, biologic, and diagnostic trials. More than 35% of these treatments are for rare or ultra-rare neurological diseases or disorders. 

Driving CNS and Neurology Treatments to Approval

Our diverse trial experience, coupled with our knowledgeable and experienced teams, allows us to confidently handle the most complex trials and patient populations with the attention and focus needed to navigate the neurological disease landscape.

At Veristat, our experienced teams are poised to plan and implement these efforts quickly providing:     



projects supported for CNS/Neurology Disorders



clinical trials are rare disorders

Veristat_icon_gene therapy


clinical trials are genetic neurological disorders

Explore Our Recent Neurology Experience

Neurology Indications
   Adrenoleukodystrophy    Epilepsy    Pain & Inflammation
   Alzheimer's Disease    Friedreich's Ataxia    Parkinson's Disease
   Amyotrophic lateral sclerosis (ALS)     Genetic Abnormalities    Pompe Disease
   Attention Deficit Disorder (ADD)    Hearing Loss    Post-Operative Pain
   Attention Deficit/Hyperactivity Disorder (ADHD)     Insomnia     Sanfilippo Syndrome
   Autism Spectrum Disorder    Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)    Schizophrenia
   Canavan Disease     Lumbar Radiculopathy     Sjogren-Larsson Syndrome (SLS)
   Cerebral Adrenoleukodystrophy (CALD)    Maroteaux-Lamy Syndrome     Sleep Apnea/ Sleep Dysfunction
   Depression     Migraine     Stroke 
   Diabetic Neuropathy Pain     Multiple Sclerosis (MS)     Spasticity Due to Spinal Cord Injury 
   Dravet Syndrome     Nocturnal Foot and/or leg cramps    Spinocerebellar Ataxia (SCA)
   Duchenne Muscular Dystrophy     Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)     Tardive Dyskinesia


Learn More with These Resources


Marketing Applications Approval Record

Veristat is proud to have supported the preparation of 75 marketing applications (NDA, BLA, MAA, etc) that are now approved for patients. For these approved products, ...


Case Study

Stem Cell Therapy for Stroke Patients

A client engaged the Veristat team in a Phase II study of intracerebral stem cell injection in patients following an ischemic stroke. The goal was to look at limb recovery ...


White Paper

Successful Preparation Strategies for  NDA/MAA Marketing ...

No two new drug applications (NDAs) or marketing authorization applications (MAAs) are the same. With each submission come special constraints, unique partnership dynamics, ...

Request A Proposal